Amgen’s Shares Plummets 5.14% Despite Record $9.2B Revenue, Ranking 63rd in $1.31B Volume

Amgen (AMGN) fell 5.14% on August 6, 2025, with a trading volume of $1.31 billion, ranking 63rd in the market. The biopharma giant reported Q2 2025 adjusted earnings of $6.02 per share, exceeding estimates, driven by 9% revenue growth to $9.2 billion. Key products like Evenity, Repatha, and Otezla delivered strong sales, while biosimilars contributed 40% year-over-year growth. However, patent expirations for Prolia and Xgeva in 2025-2026 pose risks as biosimilars erode market share.

Despite robust revenue and profit beats, Amgen’s shares dipped in after-hours trading. The company raised 2025 revenue guidance to $35-36 billion and adjusted EPS to $20.20-$21.30, citing R&D investments and potential tariff impacts. Operating margin is now projected at ~45%, down from prior forecasts, reflecting higher research costs. Meanwhile, the diabetes/obesity pipeline remains a focus, with MariTide’s phase III trials underway. This dual-action GIPR/GLP-1 drug offers monthly dosing, differentiating it from competitors like Eli Lilly and Novo Nordisk.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the effectiveness of liquidity-driven approaches in volatile markets, particularly for high-volume equities. The results underscore the importance of short-term trading strategies leveraging market concentration and rapid responsiveness to macroeconomic shifts.